Startups
Edit
SciClone Pharmaceuticals
http://www.sciclone.com/?portfolioCats=34,23,29,35,22,24,30,25,28,31#new_tabLast activity: 16.02.2026
Active
赛生药业,SciClone,赛生药业控股有限公司,SciClone Pharmaceuticals (Holdings) Limited
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 8
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 29, 2025 | ADIA takes lead role in GL Capital’s continuation vehicle for SciClone | GL Capital has brought in a wholly owned subsidiary of the Abu Dhabi Investment Authority (ADIA) as lead investor in a single-asset continuation vehicle (CV), according to a release on Monday. The vehicle will house SciClone Pharmaceuticals... |
| Nov 8, 2023 | Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer | ORSERDU is the first treatment specifically approved for patients with ER+, HER2- advanced or metastatic breast cancer tumors that harbor ESR1 mutations, representing the first innovation in endocrine therapy in nearly 20 years. ESR1 mutati... |
| Sep 20, 2022 | Menarini and SciClone Sign Exclusive Licensing Agreement to Develop and Commercialize Vaborem® in China to Treat Antimicrobial Resistant Infections | Vaborem®, a patented combination of meropenem and vaborbactam, is expected to address the rising prevalence of carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in China The deal brings together Melinta's innovation, Menarini's c... |
| Apr 23, 2021 | SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED SciClone Pharmaceuticals : Voluntary Announcement - Formation of the Strategic Cooperation with SF Pharmaceuticals to Create One-Stop F2C Supply Chain Solution in the Field of Life and Health | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| Dec 29, 2020 | SciClone se incorpora al capital de AbilityPharma, participada por Inveready, Fitalent, Sodena y el CDTI, con un compromiso de inversión de $3M | 29/12/2020 Nota de prensa SCICLONE SE INCORPORA AL CAPITAL DE ABILITYPHARMA, PARTICIPADA POR INVEREADY, FITALENT, SODENA Y EL CDTI, CON UN COMPROMISO DE INVERSIÓN DE $3 MILLONES. La empresa biofarmacéutica catalana AbilityPharma, centrad... |
| Oct 17, 2017 | Chinese consortium completes $605m buyout of Nasdaq-listed SciClone Pharma | Premium Nasdaq-listed SciClone Pharmaceuticals Inc. has been privatised and delisted from the New York-based stock exchange by a consortium consisting of entities affiliated with GL Capital Management GP Limited (GL Capital), Bank of China ... |
| Jun 8, 2017 | Term Sheet — Thursday, June 8 | You’ll Laugh! Cry! (Maybe Buy.) Below is my column from the latest issue of Fortune. Apologies if this concept sounds a tiny bit familiar to dedicated Term Sheet readers… Paid Content You can't secure what you can't see From ExtraHop Some o... |
Reviews 0
FAQ about SciClone Pharmaceuticals
What has the press written about SciClone Pharmaceuticals?
Parsers VC has collected 8 articles mentioning SciClone Pharmaceuticals, among them “ADIA takes lead role in GL Capital’s continuation vehicle for SciClone” (Sep 29, 2025) and “Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Ad...” (Nov 8, 2023).
Is SciClone Pharmaceuticals still active?
Yes, SciClone Pharmaceuticals is active; its latest activity on Parsers VC dates from Feb 16, 2026.